{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kushner BH"],"funding":["NCI NIH HHS"],"pagination":["e1016704"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4485744"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(7)"],"pubmed_abstract":["Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-G<sub>D2</sub> murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human a"],"journal":["Oncoimmunology"],"pubmed_title":["Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II study."],"pmcid":["PMC4485744"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Kuk D","Cheung NK","Modak S","Yataghene K","Kushner BH","Ostrovnaya I","Cheung IY","Kramer K"],"additional_accession":[]},"is_claimable":false,"name":"Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub> immunotherapy and isotretinoin: a prospective Phase II study.","description":"Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, however, is problematic. We report the first study providing outcome data for this group of patients with poor prognosis. To prevent another relapse, HR-NB patients in second or later CR/VGPR received the anti-G<sub>D2</sub> murine antibody 3F8 plus granulocyte-macrophage colony-stimulating factor plus isotretinoin in a Phase II trial. Upon meeting the target aim for progression-free survival (PFS) in the initial cohort of 33 patients, the trial was amended to allow patients who developed human a","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jul","modification":"2025-04-26T12:53:07.546Z","creation":"2019-03-27T01:54:15Z"},"accession":"S-EPMC4485744","cross_references":{"pubmed":["26140243"],"doi":["10.1080/2162402X.2015.1016704","10.1080/2162402x.2015.1016704"]}}